Clinical Trials Logo

Clinical Trial Summary

By this non-randomized prospective study, it's evaluated the outcome of patients underwent BCS for DCIS at whom an established score system to address adjuvant therapies have been prospectively applied, according to the wideness of free margins.

Between March 2000 and April 2006, 224 patients were enrolled and followed within the study.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT03002766
Study type Interventional
Source Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact
Status Completed
Phase Phase 2
Start date March 2000
Completion date April 2006

See also
  Status Clinical Trial Phase
Recruiting NCT05507034 - Identifying Biomarkers for Chronic Pain After Breast Cancer Treatment.
Not yet recruiting NCT05603013 - Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0) Phase 2
Completed NCT01849133 - Randomized Trial on Intraoperative Radiotherapy Full Dose Vs External Radiotherapy N/A
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Recruiting NCT04790305 - Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer Phase 4
Completed NCT03113825 - Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery Phase 2
Recruiting NCT05461430 - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Active, not recruiting NCT03768492 - Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy Phase 2